

LEVETIRACETAM THERAPEUTIC MONITORIN IN PATIENTS WITH EPILEPSY: EFFECT OF CONCOMITANT **ANTIEPILEPTIC DRUGS**

Alzueta N, Aldaz A, Egüés A.



Clínica Universidad de Navarra. Pharmacy Service (Pamplona, Spain)

BACKGROUND

Levetiracetam (LEV) is one of the newer antiepileptic drugs (AEDs). Data on LEV pharmacokinetics and interactions are limited and partly contradictory. Theoretically, LEV can be expected to have a very low potential for drug interaction since it is neither protein bound in blood nor metabolized in the liver.

PURPOSE

To evaluate the effect of concomitant AED therapy on the oral apparent clearance of LEV (Cl_{IEV}) in a population of patients with epilepsy.

METHODS

Retrospective study from 2009 to 2013, in patients with epilepsy treated with LEV in a tertiary hospital.

Variables collected were LEV dose, serum concentration, age, sex, body weight and anticonvulsant comedications prescribed. They were obtained from the therapeutic drug monitoring register and the medical records.

Serum concentrations of LEV were measured by high-performance liquid chromatography with spectrophotometric detection. Statistica v.6.0 Stat Soft® was used for statistical analysis.

SEX	104 Men (61,17%)	Group A	LEV + AED inducers of CYP	PHENOBARBITAL
	66 Women (38,83%)	(n=54)	P450	PHENYTOIN

